PharmaLeaders.com

News. Resources. Community.

  • Features
  • Channels
    • Biotech Channel
    • Clinical Channel
    • CME Channel
    • Compliance Channel
    • Device Channel
    • HIMSS Channel
    • Marketing Channel
    • Pharma Channel
    • R&D Channel
    • Telehealth Channel
    • Training Channel
  • Events
  • On Demand
  • White Papers
  • Vendors
    • Biotech Vendors
    • Clinical Vendors
    • CME Vendors
    • Compliance Vendors
    • Device Vendors
    • Marketing Vendors
    • Pharma Vendors
    • R&D Vendors
    • Training Vendors
  • Contributors

Merck signs agreement to purchase Pandion Therapeutics

02/26/2021 by PharmaLeaders Aggregator

Biopharmaceutical firm Merck has announced that it has entered into a definitive agreement to purchase Pandion Therapeutics through a subsidiary, for a total equity value of about $1.85m. The post Merck signs agreement to purchase Pandion Therapeutics appeared first on Pharmaceutical Business review. … [Read more...]

UCB expands partnership with Microsoft to speed up drug development

02/25/2021 by PharmaLeaders Aggregator

Belgium-based biopharmaceutical firm UCB has expanded its collaboration with technology company Microsoft to accelerate discovery and development of drugs for people living with severe diseases in immunology and The post UCB expands partnership with Microsoft to speed up drug development appeared first on Pharmaceutical Business review. … [Read more...]

ViiV Healthcare seeks USFDA approval to expand Cabenuva use for HIV-1 infected adults

02/25/2021 by PharmaLeaders Aggregator

Specialist HIV company ViiV Healthcare has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) to expand the use of Cabenuva. Cabenuva The post ViiV Healthcare seeks USFDA approval to expand Cabenuva use for HIV-1 infected adults appeared first on Pharmaceutical Business review. … [Read more...]

USFDA accepts priority review for Pfizer’s TicoVac

02/24/2021 by PharmaLeaders Aggregator

Pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for priority review for TicoVac, a tick-borne encephalitis The post USFDA accepts priority review for Pfizer’s TicoVac appeared first on Pharmaceutical Business review. … [Read more...]

AstraZeneca withdraws Imfinzi indication in US for bladder cancer

02/24/2021 by PharmaLeaders Aggregator

AstraZeneca has voluntarily withdrawn the Imfinzi (durvalumab) indication for adult patients who received treatment earlier in the US for locally advanced or metastatic bladder cancer. The company has The post AstraZeneca withdraws Imfinzi indication in US for bladder cancer appeared first on Pharmaceutical Business review. … [Read more...]

Next Page »
  • Facebook
  • LinkedIn
  • Twitter

Choose Your Channel

Receive event announcements and special reports directly in your inbox.
  • This field is for validation purposes and should be left unchanged.
DIA 2021 Global Annual Meeting

Upcoming Events

  1. 3rd Annual Chronic Kidney Disease Drug Development Summit

    March 2 - March 4
  2. 2nd Medical Writing Landscape Advancement Summit

    March 3 - March 4
  3. 2nd Gene Therapy for Blood Disorders

    March 9 - May 11
  4. The 3rd Bacteriophage Therapy Summit

    March 23 - March 25
  5. 11th Annual Clinical Biomarkers & World CDx Europe

    March 24 - March 25

View All Events

  • About Us
  • Sponsorship
  • Join Our Team
  • Contact Us

Copyright © 2021 PharmaLeaders.com. All rights reserved.

Copyright © 2021 · Magazine Pro Theme on Genesis Framework · WordPress · Log in